FDA Slaps Import Alert on Dabur India Over Safety Lapses

Photo: Economic Times

A major foreign manufacturer is facing the consequences of cutting corners. The US Food and Drug Administration has issued an import alert on drugs produced at Dabur India's Silvassa plant. This move blocks products from the facility from entering the United States, serving as a strong step toward protecting American consumers from potentially compromised goods.

FDA Inspectors Expose Data Integrity Failures

The FDA placed the Silvassa facility under Import Alert 66-40 on June 10, 2026. This classification allows the agency to detain products without physical examination. Inspectors cited serious data integrity and maintenance lapses at the plant, signaling a breakdown in basic operational standards.

Dabur India confirmed the federal action in a recent statement.